Proactiveinvestors recommends
Additional Information
Market:ASX
Sector:Pharma & Biotech
EPIC:CIR
Latest Price: 0.43  (-2.27% Descending)
52-week High:0.65
52-week Low:0.43
Market Cap:19.95M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Circadian Technologies

Circadian Technologies (ASX: CIR) is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses.

 

Circadian owns an extensive portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating tumour blood supply.

Pdf

Circadian Technologies appoints Dr Ian Leitch to clinical trials management team

Monday, September 12, 2011
Circadian Technologies appoints Dr Ian Leitch to clinical trials management team

Australian drug developer Circadian Technologies (ASX:CIR, OTCQX:CKDXY) has added depth to its clinical development team, appointing Dr Ian Leitch to the newly created position of director – Clinical Research.

With Circadian moving into the clinical development phase of its development in oncology and eye disease, Leitch will initially be based in the USA and will relocate to Australia in early 2012 with Circadian.

For the past 5 years he has been within the Medical Sciences group at Amgen Inc (Nasdaq: AMGN) in Thousand Oaks California, involved in the development of novel therapeutics in Amgen’s oncology pipeline.

In his role as Senior Manager in the Early Development Oncology Therapeutic Area he had responsibility for the oversight, design, management and execution of Phase 1-2 clinical studies in oncology.

Circadian’s chief executive officer, Robert Klupacs said “As we move into the clinical development phase of our development in oncology and eye disease it is critical that we have the best people managing this activity.

"We are extremely fortunate to be able to recruit someone of Ian’s experience and expertise to this key role. It is also extremely gratifying that we have been able to convince an expat Australian to return home. We believe this is a great endorsement for Circadian, our technology as well as the continuing growth and international recognition of the Australian biotechnology industry.”

Dr Leitch said “I am very excited to be returning to Australia and joining Circadian at such an important time in its evolution into a clinical stage drug development company. I believe its technology has enormous potential and that its management, advisory team and Board are world class. It is a great opportunity for me to come back to Australia and be part of the ongoing development of the Australian biotechnology industry.”

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.